Regulatory News :

DEINOVE (Paris:ALDEI) (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, today announced that one of its researchers, Erika Boulant, was selected by the scientific committee of the prestigious "Gordon Research Conference" to present her work as part of the "Multi-Drug Efflux Systems" session held in Barga, Italy, from April 26 to May 1, 2015 (https://www.grc.org/programs.aspx?id=13928).

The Gordon Research Conferences constitute an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies. These scientific conferences were initiated by Johns-Hopkins University in the USA.

Erika Boulant's work focuses on the study of the mechanisms of resistance to fermentation products in Deinococcus. This is applied research to improve the performance of the strains. Erika joined the DEINOVE team as part of the CIFRE programme1 and works in the "UMR-MD1 Transporteurs Membranaires, Chimiorésistance et Drug-Design" laboratory in Marseille. She is one of the two researchers in the team who benefit from this type of state funding through the ANRT2.

"It is a pleasure and an honour to see the work of our young researchers recognised by a high-level organisation such as the Gordon Research Conferences. Erika's work is directly applicable to the improvement of a Deinococcus-based industrial production process", commented Jean-Paul Leonetti, VP of R&D at DEINOVE. "This is recognition of the quality of State-funded CIFRE contracts, which support this collaborative research project", added Jean-Michel Bolla, Team leader in Marseille.

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro‐factories" to produce high value‐added products from non‐food biomass. The Company’s primary markets are 2nd‐generation biofuels (DEINOL) and bio‐based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.
Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs over 40 people in its new offices and laboratories located in Montpellier, France.
More information at www.deinove.com

1 The CIFRE programme - Industrial Agreements for Training through Research (Conventions Industrielles de Formation par la REcherche) - subsidises any company under French law that hires a doctoral student for research collaboration with a public laboratory. The work leads to a thesis defence in three years. Here, Erika Boulant, one of two researchers benefiting from this programme in DEINOVE laboratories, works with Aix-Marseille University.

2 French National Association for Research and Technology (Association Nationale de la Recherche et de la Technologie)